Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells

Table 3 Cell cycle distribution of U266 MM cell line treated with SSTR ligands and 7C11

Treatment	G0-G1 (%)	S (%)	G2-M (%)	Sub-G1 (%)
Control	56,6 ± 3,0	25,1 ± 2,3	12,4 ± 1,1	2,5 ± 0,3
Sst 10 μM	57,4 ± 2,0	26,3 ± 0,8	9,6 ± 1,8	3,3 ± 0,2
Css 10 μM	60,8 ± 2,4	20,7 ± 2,4	11,2 ± 0,1	3,7 ± 0,8
Sst 10 μM/Css 10 μM	57,3 ± 2,2	26,2 ± 0,9	10,0 ± 2,5	2,9 ± 0,4
7C11	39,9 ± 1,5*	26,8 ± 1,1	9,9 ± 1,0	16,0 ± 0,9*
7C11/Sst 10 μM	40,3 ± 1,8*	27,2 ± 0,4	8,6 ± 1,1	14,0 ± 0,7*
7C11/Sst 10 μM/Css 10 μM	38,3 ± 3,3*	27,3 ± 1,0	8,9 ± 0,8	12,0 ± 1,1*
Oct 10 μM	55,2 ± 4,6	25,1 ± 3,5	13,6 ± 1,5	3,0 ± 0,5
Oct 10 μM/Css 10 μM	55,6 ± 4,7	24,9 ± 3,6	12,6 ± 1,6	4,0 ± 0,8
7C11/Oct 10 μM	43,1 ± 0,5*	27,2 ± 1,7	12,2 ± 1,5	13,6 ± 1,9*
7C11/Oct 10 μM/Css 10 μM	41,9 ± 0,8*	26,4 ± 2,6	8,1 ± 0,4	18,2 ± 4,6*

U266 cells were pretreated or not (control) with Sst, Oct, Css or the agonistic Fas antibody 7C11 (7C11) for 72 h. Cells were stained with PI, analyzed by flow cytometry and each fraction of the cell cycle was determined using Wincycle^®. Data are mean ± S.E.M. of 3 independent experiments. *, ANOVA followed by Bonferroni-Dunn (p < 0.05), statistically significant differences compared to control cells.

ISSN: 1756-9966